Navigation Links
Eshelman Ventures Leads and Closes Series A Round in Asepticys, Inc., a Development Stage Company Focused on Developing Novel Media Disinfection Solutions.

Asepticys, Inc., is pleased to announce the closing of its series A round of financing with Eshelman Ventures, LLC in Wilmington, NC. “Eshelman Ventures is excited at the tremendous opportunity that Asepticys brings to the market, with truly disruptive potential in the Contact Lens Solutions market as well as numerous other applications in the health and wellness verticals’” says Fred Eshelman.

Asepticys is developing a new generation of chemically unique medical disinfection solutions that are effective across a broad spectrum of microbial pathogens and clinically beneficial in numerous medical and consumer healthcare applications.

The medical disinfection solutions contain a unique combination of sterilizing agents, creating a multiple stressor environment that kills and deactivates pathogenic organisms across all microbial kingdoms. This approach is materially different than selective disinfection using either single or dual stressors (e.g., chlorhexidine derivatives), which is currently the standard of care in medical/clinical healthcare. The disinfection solutions are minimally reactogenic and gentle enough for numerous clinical applications including topical skin disinfection, ophthalmologic, surgical, urology catheter, venous catheter and needleless IV connectors, and trauma, wound and burn site maintenance.

The disinfection solutions have been specifically engineered for clinical use and could dramatically reduce hospital-acquired and consumer healthcare-related infection, as well as improve patient outcome via reduction of nosocomial infection in postsurgical/treatment maintenance while in hospital.  According to Chad Roy, CEO, Asepticys, Inc., “At a time when the medical community, CDC and FDA are closely following public health issues in these areas and considering revisions to applicable standards, we believe this is the game-changer the contact lens solution market has been anticipating for over 30 years. This will disrupt and change the game not only in the contact lens solutions market, but in numerous applications around the world requiring sterilization.”

About Eshelman Ventures

Eshelman Ventures LLC, founded by Fred Eshelman was founded as an investment company primarily interested in private healthcare companies. Located in Wilmington, NC, Dr. Eshelman previously founded and served as CEO and Executive Chairman of Pharmaceutical Product Development prior to its sale to private equity interests as well an a number of other companies. For more information on Eshelman Ventures LLC and its investment portfolio visit

About Asepticys, Inc.

Asepticys is developing new generation chemically unique medical disinfection solutions that are effective across a broad spectrum of microbial pathogens and clinically beneficial in numerous medical and consumer healthcare applications.

We are currently focused on development of a multipurpose contact lens disinfection solution (MPDS) to be used regularly as a broad-spectrum sterilizer for daily use lens. Our solution is gentle enough to be used daily, requires minutes for complete sterilization of the lens, and is isotonically balanced for comfort. Also, because of unique combination of sterilants in our formulation, the risk of unwanted biofilm formation in cleaning/storage CL containers is essentially eliminated. For more information on Asepticys visit


Read the full story at

Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved

Related biology technology :

1. PharmaVentures Advises 3Legs Resources on its Acquisition of the Immuno-Oncology Company SalvaRx Who Announced its Admission for Trading on AIM Today
2. VisionGate Receives Strategic Investment from Trinnovate Ventures
3. PharmaVentures Advises Transgene on the Sale of Their Biopharmaceutical Manufacturing Plant
4. Flagship Ventures Brian Fiske Named To Forbes 30 Under 30 List
5. WuXi Healthcare Ventures Joins Financing Rounds for Twist Bioscience and Syros Pharmaceuticals
6. Ping An Ventures Takes Equity Stake in 20/20 GeneSystems
7. Clarus Ventures Adds Kiran Reddy, Robert DeBenedetto, and Lazar Dimitrov to Investment Team
8. BioPact Ventures, LLC Announces Appointment of Joe Dillon as Chief Executive Officer
9. PCI Ventures Company Liquid Biotech USA, Inc. Announces Raising $2M in Seed Capital to Develop its Proprietary Platform Technology for Cancer Diagnostics and Gene Discovery
10. ARCH Venture Partners, Flagship Ventures and MD Anderson Collaborate to Launch Codiak BioSciences
11. Turnstone Biologics Completes Series A Financing Led by Versant Ventures, Strengthens Management Team
Post Your Comments:
(Date:10/12/2017)... ... , ... AMRI, a global contract research, development and manufacturing ... and quality of life, will now be offering its impurity solutions as a ... requirements for all new drug products, including the finalization of ICH M7 earlier ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... its endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression ... guides is transformative for performing systematic gain-of-function studies. , This complement to ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... pathology, announced today it will be hosting a Webinar titled, “Pathology is going ... Pathology Associates , on digital pathology adoption best practices and how Proscia improves ...
(Date:10/11/2017)... Tbilisi, Georgia (PRWEB) , ... October 11, 2017 , ... ... disaster, taking the lives of over 5.5 million people each year. Especially those living ... the greenovative startup Treepex - based in one of the most pollution-affected countries globally ...
Breaking Biology Technology:
(Date:6/30/2017)... 30, 2017 Today, American Trucking Associations ... of face and eye tracking software, became the ... program. "Artificial intelligence and advanced ... monitor a driver,s attentiveness levels while on the ... to detect fatigue and prevent potential accidents, which ...
(Date:5/16/2017)... , May 16, 2017   Bridge ... health organizations, and MD EMR Systems , ... development partner for GE, have established a partnership ... Portal product and the GE Centricity™ products, including ... EMR. These new integrations will ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at . 2016 ...
Breaking Biology News(10 mins):